[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medico-economic-impact\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medico-economic-impact":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100585763","preoperative-magnetic-tracking-in-breast-surgery-in-france-french-medical-economic-study-100585763",false,"NCT06906601","Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.","MAGNETO","Inclusion Criteria:\n\n* I1. Female aged ≥ 18 years;\n* I2. Patient presenting with a unifocal and unilateral lesion of invasive carcinoma or in situ;\n* I3. Indication for first breast-conserving treatment with the need for preoperative localization of the lesion, regardless of the associated lymph node procedure;\n* I4. Patient affiliated with a health insurance system;\n* I5. Non-opposition to the study.\n\nExclusion Criteria:\n\n* E.1. Psychological, family, or sociological condition that may potentially compromise adherence to the treatment protocol and follow-up;\n* E.2. Bilateral surgery required;\n* E.3. Patient with metastatic breast cancer;\n* E.4. Multifocal or benign lesions;\n* E.5. Pregnant or breastfeeding patient;\n* E.6. Need for neoadjuvant treatment;\n* E.8. Patient under guardianship, curatorship, or deprived of liberty.","FEMALE","18 Years",{"count":19,"type":20},772,"ESTIMATED","6 Months","OBSERVATIONAL","MAGNETO is a French medico-economic study on preoperative localization in breast cancer surgery. The main objective is to conduct a cost-consequence analysis comparing magnetic clip localization with the use of metallic wires for the preoperative identification of non-palpable breast lesions. The choice of localization method is left to the physician's and center's discretion. The study is non-interventional (with only questionnaires and data collection), prospective, and multicenter, with patient follow-up lasting up to six months after breast surgery.",[25,26,27],"Breast Cancer","Medico-economic Impact","Breast Cancer Surgery",[29,30,31,32,33,34,35,36,37],"cancer","breast cancer","breast cancer surgery","preoperative localization","magnetic clip","wire localization","health economic study","Cost-consequence analysis","medico-economic","RECRUITING","2026-02-16",{"date":41,"type":42},"2026-02-17","ACTUAL",{"date":44,"type":42},"2025-04-15",{"date":46,"type":20},"2027-10-15",{"name":48,"class":49},"Centre Leon Berard","OTHER",7,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100324827","medico-economic-and-quality-of-life-impact-of-sjogren-associated-small-fiber-neuropathy-100324827","NCT03509064","Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy","The Medico-economic Impact and Quality of Life of the Small-fiber Neuropathy Associated by Using Validated Scales (SF36, DN4, PROFAD SSI, ESPRI)","SFINESS-QoLEco","Inclusion Criteria:\n\n* Definite primary Sjögren syndrome\n* Age over 18 years\n* No biologics nor immunoglobulin therapy during the 6 months before study onset\n\nArm 1: patients with a small fiber neuropathy defined by the presence of a clinical AND one paraclinical abnormality\n\n* (i) Clinical signs of small fibers involvement: thermo-algic sensory deficit or autonomic dysfunction or neuropathic pain with DN4 ≥4;\n* AND\n* (ii) Small fibers neurophysiological abnormalities (QST, laser evoked potentials, autonomic nervous system tests (sympathetic skin response test or Sudoscan®)\n* OR\n* (iii) abnormal intraepidermal nerve fiber density (skin biopsy)\n\nArm2 (control group): patients without signs of peripheral neuropathy (small or large fiber)\n\nExclusion Criteria:\n\n* Presence of other causes of peripheral neuropathy\n\n  * Acquired: Diabetes, AL amyloidosis, Alcoholism, celiac disease, Drugs, toxic, HIV, Sarcoidosis, systemic vasculitis, Guillain-Barré syndrome.\n  * Hereditary: Transthyretin hereditary amyloidosis (TTR), hereditary sensory and autonomic neuropathy (HSAN), Fabry's disease\n* Patients with impaired thermo-algic sensitivity and \u002F or dysautonomia and \u002F or pain with DN4 ≥ 4 AND normal diagnostic tests (normal neurophysiological tests AND normal skin biopsy) are excluded.","ALL",{"count":61,"type":20},100,"BACKGROUND Sjögren's syndrome is an autoimmune disease whose prevalence is estimated between 200 and 500 patients per 100,000 persons in France (120 to 500,000 patients). It affects women (90%) between 40 and 60 years of age and main manifestations are generalized sicca syndrome (ocular, oral, cutaneous) and arthralgia. In 20% of cases, Sjögren's syndrome is associated with peripheral neuropathies, and the most common form is painful small fiber neuropathy (SFN). SFNs are mainly featured by neuropathic pain including burns (90%), numbness (87.5%), tingling (72.5%), electric shocks (70%) and tingling (82.5%) and also autonomic disorders (50 to 70%).\n\nHowever, there are still important issues that deserve to be investigated by clinical and basic research. Among these issues, this study will focus on:\n\n* The impact of SFN on the quality of life of patients with Sjögren's syndrome.\n* The medico-economic impact of the SFN taking into account the repercussions on the quality of life, including professional life, usual care cost (analgesics, medical and paramedical consultations, hospitalizations or emergency).\n\nEXPECTED RESULTS\n\n* Confirmation of the major impairment in the quality of life of patients with Sjogren-associated SFN\n* Analysis of correlations to highlight or not clinical or biological factors associated with quality of life impairment.\n* Evaluation of the cost attributed to the presence of an SFN in patients with Sjögren's syndrome and the pharmaco-economic interest of conventional therapeutic management (analgesic treatment, consultation pain) compared to the cost of more aggressive immunomodulatory treatments.",[64,65,66,26],"Primary Sjögren Syndrome","Small Fiber Neuropathy","Quality of Life",[68,69,70,71],"Primary sjogren syndrome","Small fiber neuropathy","Quality of life","Medico-economic impact","2026-02-04",{"date":74,"type":42},"2026-02-05",{"date":76,"type":42},"2019-01-14",{"date":78,"type":20},"2027-01-14",{"name":80,"class":49},"Assistance Publique - Hôpitaux de Paris",1]